Challenges and Future Prospects of Precision Medicine in Psychiatry

References

• Jameson JL, Longo DL. Precision medicine — personalized, problematic, and promising. N Engl J Med. 2015;372(23):2229–2234. doi:10.1056/NEJMsb150310426014593
   PubMed Web of Science ®Google Scholar
• Ashley EA. Towards precision medicine. Nat Rev Genet. 2016;17(9):507. doi:10.1038/nrg.2016.8627528417
   PubMed Web of Science ®Google Scholar
• Tonelli MR, Shirts BH. Knowledge for precision medicine: mechanistic reasoning and methodological pluralism. JAMA. 2017;318(17):1649–1650. doi:10.1001/jama.2017.1191429052713
   PubMed Web of Science ®Google Scholar
• Häfner H. Descriptive psychopathology, phenomenology, and the legacy of Karl Jaspers. Dialogues Clin Neurosci. 2015;17(1):19–29.25987860
   PubMed Web of Science ®Google Scholar
• Alda M. Personalized psychiatry: many questions, fewer answers. J Psychiatry Neurosci. 2013;38(6):363–365. doi:10.1503/jpn.13022124148844
   PubMed Web of Science ®Google Scholar
• Le Tourneau C, Delord J-P, Gonçalves A, et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol. 2015;16(13):1324–1334. doi:10.1016/S1470-2045(15)00188-626342236
   PubMed Web of Science ®Google Scholar
• June CH, O’Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018;359(6382):1361–1365. doi:10.1126/science.aar671129567707
   PubMed Web of Science ®Google Scholar
• Carroll B. Clinical applications of the dexamethasone suppression test for endogenous depression. Pharmacopsychiatry. 1982;15(01):19–25. doi:10.1055/s-2007-1019504
   Web of Science ®Google Scholar
• Barlow DH. On the relation of clinical research to clinical practice: current issues, new directions. J Consult Clin Psychol. 1981;49(2):147. doi:10.1037/0022-006X.49.2.1477217481
   PubMed Web of Science ®Google Scholar
• LeFort SM. The statistical versus clinical significance debate. Image J Nurs Sch. 1993;25(1):57–62. doi:10.1111/j.1547-5069.1993.tb00754.x8240480
   PubMedGoogle Scholar
• Hicks JK, Bishop JR, Sangkuhl K, et al. Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin Pharmacol Ther. 2015;98(2):127–134. doi:10.1002/cpt.14725974703
   PubMed Web of Science ®Google Scholar
• Hicks J, Sangkuhl K, Swen J, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37–44. doi:10.1002/cpt.59727997040
   PubMed Web of Science ®Google Scholar
• Brown JT, Bishop JR, Sangkuhl K, et al. Clinical pharmacogenetics implementation consortium guideline for cytochrome P450 (CYP)2D6 genotype and atomoxetine therapy. Clin Pharmacol Ther. 2019;106(1):94–102. doi:10.1002/cpt.140930801677
   PubMed Web of Science ®Google Scholar
• Phillips EJ, Sukasem C, Whirl-Carrillo M, et al. Clinical pharmacogenetics implementation consortium guideline for HLA genotype and use of carbamazepine and oxcarbazepine: 2017 update. Clin Pharmacol Ther. 2018;103(4):574–581. doi:10.1002/cpt.100429392710
   PubMed Web of Science ®Google Scholar
• Caudle K, Klein T, Hoffman J, et al. Incorporation of pharmacogenomics into routine clinical practice: the clinical pharmacogenetics implementation consortium (CPIC) guideline development process. Curr Drug Metab. 2014;15(2):209–217. doi:10.2174/138920021566614013012491024479687
   PubMed Web of Science ®Google Scholar
• Lunenburg CATC, van der Wouden CH, Nijenhuis M, et al. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene–drug interaction of DPYD and fluoropyrimidines. Eur J Hum Genet. 2020;28(4):508–517. doi:10.1038/s41431-019-0540-031745289
   PubMed Web of Science ®Google Scholar
• Caudle KE, Sangkuhl K, Whirl-Carrillo M, et al. Standardizing CYP2D6 genotype to phenotype translation: consensus recommendations from the clinical pharmacogenetics implementation consortium and Dutch pharmacogenetics working group. Clin Transl Sci. 2020;13(1):116–124. doi:10.1111/cts.1269231647186
   PubMed Web of Science ®Google Scholar
• Liu Y, Chen PHC, Krause J, Peng L. How to read articles that use machine learning: users’ guides to the medical literature. JAMA. 2019;322(18):1806–1816. doi:10.1001/jama.2019.1648931714992
   PubMed Web of Science ®Google Scholar
• Tarca AL, Carey VJ, Chen XW, Romero R, Drǎghici S. Machine learning and its applications to biology. PLoS Comput Biol. 2007;3(6):e116. doi:10.1371/journal.pcbi.003011617604446
   PubMed Web of Science ®Google Scholar
• Beam AL, Manrai AK, Ghassemi M. Challenges to the reproducibility of machine learning models in health care. JAMA. 2020;323(4):305. doi:10.1001/jama.2019.20866
   PubMed Web of Science ®Google Scholar
• Doshi-Velez F, Perlis RH. Evaluating machine learning articles. JAMA. 2019;322(18):1777–1779. doi:10.1001/jama.2019.1730431714974
   PubMed Web of Science ®Google Scholar
• Kim TT, Dufour S, Xu C, et al. Predictive modeling for response to lithium and quetiapine in bipolar disorder. Bipolar Disord. 2019;21(5):428–436. doi:10.1111/bdi.1275230729637
   PubMed Web of Science ®Google Scholar
• Nunes A, Ardau R, Berghöfer A, et al. Prediction of lithium response using clinical data. Acta Psychiatr Scand. 2020;141(2):131–141. doi:10.1111/acps.1312231667829
   PubMed Web of Science ®Google Scholar
• Fleck DE, Ernest N, Adler CM, et al. Prediction of lithium response in first-episode mania using the LITHium Intelligent Agent (LITHIA): pilot data and proof-of-concept. Bipolar Disord. 2017;19(4):259–272. doi:10.1111/bdi.1250728574156
   PubMed Web of Science ®Google Scholar
• Perlis RH. A clinical risk stratification tool for predicting treatment resistance in major depressive disorder. Biol Psychiatry. 2013;74(1):7–14. doi:10.1016/j.biopsych.2012.12.00723380715
   PubMed Web of Science ®Google Scholar
• Nie Z, Vairavan S, Narayan VA, Ye J, Li QS. Predictive modeling of treatment resistant depression using data from STAR*D and an independent clinical study. PLoS One. 2018;13(6):e0197268. doi:10.1371/journal.pone.019726829879133
   PubMed Web of Science ®Google Scholar
• Talpalaru A, Bhagwat N, Devenyi GA, Lepage M, Chakravarty MM. Identifying schizophrenia subgroups using clustering and supervised learning. Schizophr Res. 2019;214:51–59. doi:10.1016/j.schres.2019.05.04431455518
   PubMed Web of Science ®Google Scholar
• Brodey BB, Girgis RR, Favorov OV, et al. The Early Psychosis Screener for Internet (EPSI)-SR: predicting 12 month psychotic conversion using machine learning. Schizophr Res. 2019;208:390–396. doi:10.1016/j.schres.2019.01.01530777603
   PubMed Web of Science ®Google Scholar
• Fond G, Bulzacka E, Boucekine M, et al. Machine learning for predicting psychotic relapse at 2 years in schizophrenia in the national FACE-SZ cohort. Prog Neuropsychopharmacol Biol Psychiatry. 2019;92:8–18. doi:10.1016/j.pnpbp.2018.12.00530552914
   PubMed Web of Science ®Google Scholar
• Koutsouleris N, Kahn RS, Chekroud AM, et al. Multisite prediction of 4-week and 52-week treatment outcomes in patients with first-episode psychosis: a machine learning approach. Lancet Psychiatry. 2016;3(10):935–946. doi:10.1016/S2215-0366(16)30171-727569526
   PubMed Web of Science ®Google Scholar
• Alda M. Who are excellent lithium responders and why do they matter? World Psychiatry. 2017;16(3):319–320. doi:10.1002/wps.2046228941103
   PubMed Web of Science ®Google Scholar
• Alda M. Lithium in the treatment of bipolar disorder: pharmacology and pharmacogenetics. Mol Psychiatry. 2015;20(6):661–670. doi:10.1038/mp.2015.425687772
   PubMed Web of Science ®Google Scholar
• Kleindienst N, Engel R, Greil W. Which clinical factors predict response to prophylactic lithium? A systematic review for bipolar disorders. Bipolar Disord. 2005;7(5):404–417. doi:10.1111/j.1399-5618.2005.00244.x16176433
   PubMed Web of Science ®Google Scholar
• Hui TP, Kandola A, Shen L, et al. A systematic review and meta analysis of clinical predictors of lithium response in bipolar disorder. Acta Psychiatr Scand. 2019;140(2):94–115. doi:10.1111/acps.1306231218667
   PubMed Web of Science ®Google Scholar
• Grof P, Duffy A, Cavazzoni P, et al. Is response to prophylactic lithium a familial trait? J Clin Psychiatry. 2002;63(10):942–947. doi:10.4088/JCP.v63n101312416605
   PubMed Web of Science ®Google Scholar
• Thase ME. Treatment-resistant depression. J Clin Psychiatry. 2011;72(05):e18. doi:10.4088/JCP.8133tx4c21658343
   PubMed Web of Science ®Google Scholar
• Manchia M, Cullis J, Turecki G, Rouleau GA, Uher R, Alda M. The impact of phenotypic and genetic heterogeneity on results of genome wide association studies of complex diseases. PLoS One. 2013;8(10):e76295. doi:10.1371/journal.pone.007629524146854
   PubMed Web of Science ®Google Scholar
• Lee Y, Ragguett R-M, Mansur RB, et al. Applications of machine learning algorithms to predict therapeutic outcomes in depression: a meta-analysis and systematic review. J Affect Disord. 2018;241:519–532. doi:10.1016/j.jad.2018.08.07330153635
   PubMed Web of Science ®Google Scholar
• Serretti A, Smeraldi E. Neural network analysis in pharmacogenetics of mood disorders. BMC Med Genet. 2004;5(1):27. doi:10.1186/1471-2350-5-2715588300
   PubMedGoogle Scholar
• Bartova L, Dold M, Kautzky A, et al. Results of the European Group for the study of resistant depression (GSRD) - basis for further research and clinical practice. World J Biol Psychiatry. 2019;20(6):427–448. doi:10.1080/15622975.2019.163527031340696
   PubMed Web of Science ®Google Scholar
• Kautzky A, Baldinger P, Souery D, et al. The combined effect of genetic polymorphisms and clinical parameters on treatment outcome in treatment-resistant depression. Eur Neuropsychopharmacol. 2015;25(4):441–453. doi:10.1016/j.euroneuro.2015.01.00125769916
   PubMed Web of Science ®Google Scholar
• Maciukiewicz M, Marshe VS, Hauschild A-C, et al. GWAS-based machine learning approach to predict duloxetine response in major depressive disorder. J Psychiatr Res. 2018;99:62–68. doi:10.1016/j.jpsychires.2017.12.00929407288
   PubMed Web of Science ®Google Scholar
• Guilloux J-P, Bassi S, Ding Y, et al. Testing the predictive value of peripheral gene expression for nonremission following citalopram treatment for major depression. Neuropsychopharmacology. 2015;40(3):701–710. doi:10.1038/npp.2014.22625176167
   PubMed Web of Science ®Google Scholar
• Athreya A, Iyer R, Neavin D, et al. Augmentation of physician assessments with multi-omics enhances predictability of drug response: a case study of major depressive disorder. IEEE Comput Intell Mag. 2018;13(3):20–31. doi:10.1109/MCI.2018.284066030467458
   PubMed Web of Science ®Google Scholar
• Pei C, Sun Y, Zhu J, et al. Ensemble learning for early-response prediction of antidepressant treatment in major depressive disorder. J Magn Reson Imaging. 2019. doi:10.1002/jmri.27029
   Web of Science ®Google Scholar
• Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003;54(5):573–583. doi:10.1016/S0006-3223(02)01866-812946886
   PubMed Web of Science ®Google Scholar
• Chang B, Choi Y, Jeon M, et al. ARPNet: antidepressant response prediction network for major depressive disorder. Genes (Basel). 2019;10(11):907. doi:10.3390/genes10110907
   Web of Science ®Google Scholar
• Pisanu C, Squassina A. Treatment-resistant schizophrenia: insights from genetic studies and machine learning approaches. Front Pharmacol. 2019;10:617. doi:10.3389/fphar.2019.0061731191325
   PubMed Web of Science ®Google Scholar
• Vivian-Griffiths T, Baker E, Schmidt KM, et al. Predictive modeling of schizophrenia from genomic data: comparison of polygenic risk score with kernel support vector machines approach. Am J Med Genet B Neuropsychiatr Genet. 2019;180(1):80–85. doi:10.1002/ajmg.b.3270530516002
   PubMed Web of Science ®Google Scholar
• Hamshere ML, Walters JTR, Smith R, et al. Genome-wide significant associations in schizophrenia to ITIH3/4, CACNA1C and SDCCAG8, and extensive replication of associations reported by the Schizophrenia PGC. Mol Psychiatry. 2013;18(6):708–712. doi:10.1038/mp.2012.6722614287
   PubMed Web of Science ®Google Scholar
• Schizophrenia Working Group of the Psychiatric Genomic Consortium. Biological insights from 108 schizophrenia-associated genetic loci. Nature. 2014;511(7510):421–427. doi:10.1038/nature1359525056061
   PubMed Web of Science ®Google Scholar
• Boloc D, Gortat A, Cheng-Zhang JQ, et al. Improving pharmacogenetic prediction of extrapyramidal symptoms induced by antipsychotics. Transl Psychiatry. 2018;8(1):276. doi:10.1038/s41398-018-0330-430546092
   PubMed Web of Science ®Google Scholar
• Mas S, Gassó P, Ritter MA, Malagelada C, Bernardo M, Lafuente A. Pharmacogenetic predictor of extrapyramidal symptoms induced by antipsychotics: multilocus interaction in the mTOR pathway. Eur Neuropsychopharmacol. 2015;25(1):51–59. doi:10.1016/j.euroneuro.2014.11.01125499605
   PubMed Web of Science ®Google Scholar
• Martín-Flores N, Fernández-Santiago R, Antonelli F, et al. MTOR pathway-based discovery of genetic susceptibility to L-DOPA-induced dyskinesia in Parkinson’s disease patients. Mol Neurobiol. 2019;56(3):2092–2100. doi:10.1007/s12035-018-1219-129992529
   PubMed Web of Science ®Google Scholar
• Juengst E, McGowan ML, Fishman JR, Settersten Jr RA. From “personalized” to “precision” medicine: the ethical and social implications of rhetorical reform in genomic medicine. Hastings Cent Rep. 2016;46(5):21–33. doi:10.1002/hast.61427649826
   PubMed Web of Science ®Google Scholar
• Ball TM, Kalinowski A, Williams LM. Ethical implementation of precision psychiatry. Pers Med Psychiatry. 2019;19:100046.
   Google Scholar
• Carpiniello B, Pinna F. The reciprocal relationship between suicidality and stigma. Front Psychiatry. 2017;8:35. doi:10.3389/fpsyt.2017.0003528337154
   PubMed Web of Science ®Google Scholar
• Plumpton CO, Pirmohamed M, Hughes DA. Cost effectiveness of panel tests for multiple pharmacogenes associated with adverse drug reactions: an evaluation framework. Clin Pharmacol Ther. 2019;105(6):1429–1438. doi:10.1002/cpt.131230466189
   PubMed Web of Science ®Google Scholar
• Hay AE, Cheung MC. CAR T-cells: costs, comparisons, and commentary. J Med Econ. 2019;22(7):613–615. doi:10.1080/13696998.2019.158205930747012
   PubMed Web of Science ®Google Scholar
• Health Quality Ontario. Pharmacogenomic testing for psychotropic medication selection: a systematic review of the assurex genesight psychotropic test. Ont Health Technol Assess Ser. 2017;17(4):1–39.
   Google Scholar
• Tanner J-A, Brown LC, Yu K, Li J, Dechairo BM. Canadian medication cost savings associated with combinatorial pharmacogenomic guidance for psychiatric medications. Clinicoecon Outcomes Res. 2019;11:779–787. doi:10.2147/CEOR.S22427731849503
   PubMed Web of Science ®Google Scholar
• Brown LC, Lorenz RA, Li J, Dechairo BM. Economic utility: combinatorial pharmacogenomics and medication cost savings for mental health care in a primary care setting. Clin Ther. 2017;39(3):592–602.e1. doi:10.1016/j.clinthera.2017.01.02228238356
   PubMed Web of Science ®Google Scholar
• Jablonski MR, Lorenz R, Li J, Dechairo BM. Economic outcomes following combinatorial pharmacogenomic testing for elderly psychiatric patients. J Geriatr Psychiatry Neurol. 2019;891988719892341.31842673
   PubMed Web of Science ®Google Scholar
• Squassina A, Manchia M, Manolopoulos VG, et al. Realities and expectations of pharmacogenomics and personalized medicine: impact of translating genetic knowledge into clinical practice. Pharmacogenomics. 2010;11(8):1149–1167. doi:10.2217/pgs.10.9720712531
   PubMed Web of Science ®Google Scholar
• Anaya J-M, Duarte-Rey C, Sarmiento-Monroy JC, Bardey D, Castiblanco J, Rojas-Villarraga A. Personalized medicine. Closing the gap between knowledge and clinical practice. Autoimmun Rev. 2016;15(8):833–842. doi:10.1016/j.autrev.2016.06.00527302209
   PubMed Web of Science ®Google Scholar
• Ta R, Cayabyab MAS, Coloso R. Precision medicine: a call for increased pharmacogenomic education. Per Med. 2019;16(3):233–245. doi:10.2217/pme-2018-010731025601
   PubMed Web of Science ®Google Scholar
• Kohane IS. Ten things we have to do to achieve precision medicine. Science. 2015;349(6243):37–38. doi:10.1126/science.aab132826138968
   PubMed Web of Science ®Google Scholar
• Rohrer Vitek CR, Abul-Husn NS, Connolly JJ, et al. Healthcare provider education to support integration of pharmacogenomics in practice: the eMERGE network experience. Pharmacogenomics. 2017;18(10):1013–1025.28639489
   PubMed Web of Science ®Google Scholar
• Zavorotnyy M, Ehrlich F, Nenadic I. Health-related Internet use and treatment adherence: a transdiagnostic comparison of outpatients with major depressive disorder and schizophrenia. Psych J. 2020. doi:10.1002/pchj.355
   Web of Science ®Google Scholar
• Arandjelovic K, Eyre HA, Lenze E, Singh AB, Berk M, Bousman C. The role of depression pharmacogenetic decision support tools in shared decision making. J Neural Transm. 2019;126(1):87–94. doi:10.1007/s00702-017-1806-829082439
   PubMed Web of Science ®Google Scholar
• Hillyer GC, Schmitt KM, Reyes A, et al. Community education to enhance the more equitable use of precision medicine in Northern Manhattan. J Genet Couns. 2020;29(2):247–258. doi:10.1002/jgc4.124432157769
   PubMed Web of Science ®Google Scholar
• Sandstrom A, Sahiti Q, Pavlova B, Uher R. Offspring of parents with schizophrenia, bipolar disorder, and depression. Psychiatr Genet. 2019;29(5):160–169. doi:10.1097/YPG.000000000000024031464997
   PubMed Web of Science ®Google Scholar
• Oliver D, Radua J, Reichenberg A, Uher R, Fusar-Poli P. Psychosis polyrisk score (PPS) for the detection of individuals at-risk and the prediction of their outcomes. Front Psychiatry. 2019;10:174. doi:10.3389/fpsyt.2019.0017431057431
   PubMed Web of Science ®Google Scholar
• Iorfino F, Scott EM, Carpenter JS, et al. Clinical stage transitions in persons aged 12 to 25 years presenting to early intervention mental health services with anxiety, mood, and psychotic disorders. JAMA Psychiatry. 2019;76(11):1167. doi:10.1001/jamapsychiatry.2019.2360
   PubMed Web of Science ®Google Scholar
• Scott J, Hidalgo-Mazzei D, Strawbridge R, et al. Prospective cohort study of early biosignatures of response to lithium in bipolar-I-disorders: overview of the H2020-funded R-LiNK initiative. Int J Bipolar Disord. 2019;7(1):20. doi:10.1186/s40345-019-0156-x31552554
   PubMed Web of Science ®Google Scholar
• Manchia M, Squassina A, Pisanu C, et al. Investigating the relationship between melatonin levels, melatonin system, microbiota composition and bipolar disorder psychopathology across the different phases of the disease. Int J Bipolar Disord. 2019;7(1):27. doi:10.1186/s40345-019-0163-y31814040
   PubMed Web of Science ®Google Scholar